Prediction of resistance to chemotherapy in ovarian cancer: a systematic review

[1] Li M(2013)Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo Oncology Rep 29 58-66

[2] Yin J(1999)Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings Obstet Gynecol 93 21-4

[3] Mao N(2002)Relapsed ovarian cancer: challenges and management strategies for a chronic disease The Oncologist 7 20-8

[4] Pan L(2005)Cancer cell adaptation to chemotherapy BMC Cancer 5 78-91

[5] Rubin SC(2013)Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol 24 83-7

[6] Randall TC(2007)Prognostic factors for stage iii epithelial ovarian cancer: a gynecologic oncology group study J Clin Oncol 25 3621-22

[7] Armstrong KA(2009)Mammaprint Expert Rev Mol Diagn 9 417-65

[8] Chi DS(1977) 70-gene signature: another milestone in personalized medical care for breast cancer patients J Am Stat Assoc 72 557-13

[9] Hoskins WJ(2011)The efficiency of cox’s likelihood function for censored data Proc Nat Acad Sci 108 18708-9

[10] Armstrong DK(2010)Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance Curr Opin Pharmacol 10 375-36

[1] Li M(2013)Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo Oncology Rep 29 58-66

[2] Yin J(1999)Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings Obstet Gynecol 93 21-4

[3] Mao N(2002)Relapsed ovarian cancer: challenges and management strategies for a chronic disease The Oncologist 7 20-8

[4] Pan L(2005)Cancer cell adaptation to chemotherapy BMC Cancer 5 78-91

[5] Rubin SC(2013)Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol 24 83-7

[6] Randall TC(2007)Prognostic factors for stage iii epithelial ovarian cancer: a gynecologic oncology group study J Clin Oncol 25 3621-22

[7] Armstrong KA(2009)Mammaprint Expert Rev Mol Diagn 9 417-65

[8] Chi DS(1977) 70-gene signature: another milestone in personalized medical care for breast cancer patients J Am Stat Assoc 72 557-13

[9] Hoskins WJ(2011)The efficiency of cox’s likelihood function for censored data Proc Nat Acad Sci 108 18708-9

[10] Armstrong DK(2010)Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance Curr Opin Pharmacol 10 375-36